# US 2023/0407373 A1 · Rna interactome capturing protocol and antiviral composition discovered using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0407373 A1
- Document ID: US20230407373A1
- Status: Published application
- Kind: A1
- Application number: 18/034,908
- Filed: 2021-11-02
- Published: 2023-12-21
- Earliest claimed: 2020-11-02
- Assignees: Seoul National University R&Db Foundation; Institute for Basic Science
- Applicants: Seoul National University R&Db Foundation; Institute for Basic Science
- Inventors: V. Narry KIM; Sungyul LEE; Young-suk LEE
- Web page: https://patentgrep.com/patent/US20230407373A1

## CPC

- C12Q 1/6816: characterised by the detection means (C12Q1/6804 takes precedence)
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/1709: {from mammals}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/701: {Specific hybridization probes}
- G01N 33/5023: {on expression patterns}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- C12Y 304/21004: Trypsin (3.4.21.4)
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Y: ENZYMES

## Abstract

The present invention relates to an RNA interactome capturing protocol and an antiviral composition discovered using same. When used, the antiviral composition and pharmaceutical composition of the present invention can effectively inhibit viral infection and suppress viral proliferation in vivo after viral infection.

## Claims

### Claim at position 1

-9. (canceled)

### Claim 10

A screening method for a coronavirus inhibitor comprising the following steps:
(a) contacting coronavirus-infected cells with a candidate substance for a coronavirus inhibitor; and
(b) analyzing whether the expression level of one or more proteins selected from the group consisting of EIF3A, EIF3D, CSDE1, HNRNPM, YBX3, FMR1, RTCB, and NUFIP2 is reduced compared to a control group of cells not treated with the candidate substance, to determine the candidate substance as a coronavirus inhibitor if the expression level of the proteins is reduced.

### Claim 11

A method for establishing an RNA interactome comprising the following steps:
(a) inducing the RNA-protein cross-linking by irradiating a sample containing target RNA and protein with UV light;
(b) performing Denaturation by DNase treatment;
(c) capturing denatured RNP complexes in a sequence-specific manner using a biotinylated antisense oligonucleotide probe pool; wherein the biotinylated antisense oligonucleotides included in the probe pool are designed based on the target RNA sequence in a consecutive manner, and have the same length ranging from 45 to 135 nt, and their starting positions are spaced at regular intervals to induce partial overlap between the oligonucleotides;
(d) performing Digestion by on-bead trypsin treatment; and
(e) obtaining interactome information through analysis of the digestion products.

### Claim 12 (depends on 11)

The method of claim 11, wherein the target RNA is genomic RNA (gRNA) of an RNA virus.

### Claim 13 (depends on 11)

The method of claim 11, wherein the probe pool comprises a first probe pool that specifically hybridizes with a gRNA molecule and a second probe pool that hybridizes with both gRNA and sqRNA (subgenomic RNA).

### Claim 14

A method for treating virus infection, comprising a step of administering an antiviral composition to a subject in need of administration, wherein the antiviral composition comprises one or more proteins selected from the group consisting of LARP1, FUBP3, FUBP1, FAM120A, FAM120C, EIF4H, RPS3, RPS9, SND1, CELF1, RALY, CNBP, TRIM25, ZC3HAV1, PARP12, PPP1CA, HDLBP, CNBP, TIAL, UPF1, and SHFL as an active ingredient.

### Claim 15 (depends on 14)

The method of claim 14, wherein the antiviral composition comprises nucleic acids encoding one or more proteins selected from the group consisting of LARP1, FUBP3, FUBP1, FAM120A, FAM120C, EIF4H, RPS3, RPS9, SND1, CELF1, RALY, CNBP, TRIM25, ZC3HAV1, PARP12, PPP1CA, HDLBP, CNBP, TIAL, UPF1, and SHFL as an active ingredient.

### Claim 16 (depends on 14)

The method of claim 14, wherein the virus is a coronavirus.

### Claim 17 (depends on 16)

The method of claim 16, wherein the coronavirus is selected from the group consisting of 229E, OC43, NL63, HKU1, MERS-CoV, SARS-CoV and SARS-CoV-2.

### Claim 18 (depends on 14)

The method of claim 14, wherein the antiviral composition comprises a recombinant vector that contains nucleic acids encoding one or more proteins selected from the group consisting of LARP1, FUBP3, FUBP1, FAM120A, FAM120C, EIF4H, RPS3, RPS9, SND1, CELF1, RALY, CNBP, TRIM25, ZC3HAV1, PARP12, PPP1CA, HDLBP, CNBP, TIAL, UPF1, and SHFL as an active ingredient.

### Claim 19 (depends on 14)

The method of claim 14, wherein the antiviral composition comprises an expression inhibitor or activity inhibitor of one or more proteins selected from the group consisting of EIF3A, EIF3D, CSDE1, HNRNPM, YBX3, FMR1, RTCB, and NUFIP2.

### Claim 20 (depends on 19)

The method of claim 19, wherein the expression inhibitor of the proteins is selected from the group consisting of miRNA, siRNA, shRNA, antisense oligonucleotide, CRISPRi, and combinations thereof that complementarily bind to the nucleic acid sequences encoding the proteins.

### Claim 21 (depends on 19)

The method of claim 19, wherein the activity inhibitor of the proteins is selected from the group consisting of antibodies, aptamers, small molecule compounds, and combinations thereof that specifically bind to the proteins.
